Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma (NCT00897910), a registered phase not stated study. The primary outcome is Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry.

2. Clinical Question

The clinical question is therefore about whether and how myeloma-specific T cells can be identified and expanded in laboratory work using patient samples. The stated purpose is to study T cells in blood and bone marrow samples from patients with multiple myeloma. The brief summary frames the research as a way to learn more about these cells and to inform future treatment planning; it does not describe a treatment being assigned to participants or a clinical outcome being compared between groups.

The official title specifies use of autologous B cells as antigen-presenting cells, while the listed intervention descriptions include laboratory techniques. These details describe the research approach, but the registry record does not report a complete laboratory protocol, a comparison condition, or a numerical result for the primary question. It also does not report whether the planned laboratory strategy achieved a particular degree of cell expansion. Interpretation must therefore remain focused on the study’s stated question and the absence of posted outcome estimates.

3. Trial Design

The registry classifies this as an “other” study and lists the status as terminated. The listed enrollment is 6. The start date is 2008-04, and the primary completion date is 2009-11. Those registry entries establish the study’s recorded status and timing, but the reason for termination and the circumstances of enrollment are not reported in the registry record.

The research concerns collection and laboratory study of blood and bone marrow samples from patients with multiple myeloma. The primary outcome timeframe states that PBMCs are collected over a period of 9-12 months and that the laboratory component is performed over another year. The record does not give further details about the collection schedule, eligibility criteria, or the laboratory workflow. It names flow cytometry, an immunoenzyme technique, and laboratory biomarker analysis, but does not specify how each technique is assigned to a particular measurement.

This is not described as a randomized trial or a comparison of clinical treatments. The registry record does not identify a conventional control group, and the listed activities are laboratory techniques rather than treatment arms. Consequently, a between-arm treatment effect is not the natural interpretation of the stated study purpose. The record does not report allocation methods, masking, or a protocol-defined comparison group.

The primary outcome is the percentage of myeloma-specific T cells expanded ex vivo using flow cytometry. A secondary outcome concerns cell counts of myeloma-specific T cells expanded ex vivo before and after CD3/CD28 stimulation. Although the record lists two outcome measures, it contains no posted analysis entries and no numerical estimates for either measure. It also does not report the planned sample-size justification, interim analyses, or a complete statistical analysis plan.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: All 6 consented subjects had blood drawn during their routine labs. No bone marrow samples were collected.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry, measured over Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year..

The primary endpoint is titled “Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry.” It is intended to describe the proportion of cells meeting the study’s definition of myeloma-specific T cells after laboratory expansion. Flow cytometry is a method for distinguishing and counting cells based on measured characteristics. In general, a percentage can express the share of cells classified as belonging to a target group relative to a defined total. The registry record does not specify the denominator, cell-identification criteria, or calculation details for this endpoint.

Using a percentage may help characterize the composition of an expanded cell population rather than reporting only its overall size. That distinction matters generally: a sample may contain many cells while the share with the characteristic of interest differs, or a share may be reported without conveying the total cell count. The registry also names a secondary outcome based on cell counts before and after CD3/CD28 stimulation, which addresses cell quantity rather than the primary endpoint’s stated percentage.

The endpoint is a laboratory measure, not a clinical outcome such as symptoms, disease progression, or survival. The registry’s primary outcome timeframe describes PBMC collection over 9-12 months followed by a laboratory component over another year. No observed percentage, unit, dispersion measure, or numerical result is reported in the registry record. The endpoint’s exact operational definition and the way results were summarized are also not reported in the registry record. Accordingly, the endpoint title identifies the intended measurement, but does not by itself establish what was observed.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods can only be interpreted when the measurement, analysis population, comparison, and uncertainty are described. The registry record provides a primary endpoint title and a secondary outcome title, but it does not provide a statistical analysis plan or completed analysis entries. The discussion below therefore explains general statistical concepts relevant to these kinds of measures; it does not describe methods known to have been used in this study.

What does a percentage measure?

In general, a percentage describes a numerator as a share of a defined denominator. For a cell percentage, the numerator would ordinarily be the cells classified as meeting a target definition, while the denominator would be the larger cell population against which that share is calculated. The definition of both parts is essential: changing the cell-identification rules or the denominator can change the meaning of the percentage. The registry record does not report the operational definition, gating rules, denominator, or calculation method for the primary endpoint. It therefore does not permit independent reconstruction or detailed evaluation of the measure.

A percentage also differs from an absolute cell count. A percentage describes composition; a count describes quantity. The named secondary outcome concerns cell counts before and after stimulation, while the primary outcome concerns a percentage after ex vivo expansion. These are related but not interchangeable types of measurement. General interpretation should consider each endpoint on its own scale and should not presume that an increase in one necessarily corresponds to a particular change in the other.

What would an estimate and confidence interval add?

In general, an estimate gives a summary of the observed data, and a confidence interval conveys sampling uncertainty under the assumptions of the chosen method. The interval is useful because the same point estimate can be compatible with either relatively precise or highly uncertain evidence. Its interpretation also depends on whether observations are independent and whether the model matches the data-generating process. Here, no primary estimate, confidence interval, standard error, or other measure of uncertainty is reported in the registry record. Precision cannot therefore be assessed from the posted registry entries.

For a cell percentage, statistical methods may need to account for the number of cells measured and the structure of sampling. Cells measured within one participant or specimen are not automatically equivalent to independent participants. General methods can account for clustering or repeated observations when such structure is present, but the registry record does not describe the data structure or the analysis unit. It does not say whether analyses were based on participant-level summaries, specimen-level results, or cell-level observations. No particular model should be attributed to this study.

Why can over-dispersion matter?

In general, count and proportion data may vary more than a simple statistical model expects. This is called over-dispersion. If it is ignored, a model can understate uncertainty and make results appear more precise than the data justify. Potential sources of extra variability in laboratory measurements can include differences among participants, specimens, or measurement processes; whether any of these occurred in this study is not reported in the registry record. A suitable analysis would depend on the observed data and the measurement protocol, neither of which is described in enough detail to identify a model.

For paired measurements, such as a measure taken before and after a laboratory procedure, the analysis generally needs to preserve the link between observations from the same participant or specimen. Treating paired values as unrelated can discard information or misstate uncertainty. The secondary outcome title refers to cell counts before and after CD3/CD28 stimulation, but the record does not describe pairing, the number of observations, or the statistical test or model used. It also reports no numerical before-and-after results. No conclusion about a change can be drawn from the outcome title alone.

What do the planning assumptions mean?

General sample-size planning asks how many observations a future study might need to detect a specified effect under stated assumptions. The planning assumptions described for the associated illustrations use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is expressed as a stated fraction of the observed effect. Such figures are planning illustrations, not observed power and not evidence that the study enrolled participants according to those assumptions. The registry record does not report the study’s own sample-size justification.

Those two-arm assumptions should not be confused with this registry’s design description. The record does not identify a randomized, like-for-like two-arm comparison. Its listed interventions are laboratory techniques, and its focus is the study of samples. Thus, a generic calculation that assumes equal allocation between arms is not a description of how this study was conducted. The record does not report the assumptions used to plan this study, an effect size used for its design, or a protocol-based target enrollment rationale.

Finally, multiplicity, missing observations, analysis populations, and interim analyses can affect how results should be interpreted. The registry record does not report a multiplicity strategy, missing-data procedures, analysis-population definitions, interim analyses, or a statistical analysis plan. These absences do not establish that such procedures were or were not used; they mean their use cannot be evaluated from the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists two outcome measures: the primary percentage of myeloma-specific T cells expanded ex vivo using flow cytometry and a secondary cell-count measure before and after CD3/CD28 stimulation. It does not report a multiplicity strategy, such as a method for controlling the interpretation of several statistical tests. No analysis entries or inferential results are listed, so the potential effects of multiple testing cannot be assessed from the posted record.

Missing-data procedures are not reported in the registry record. The listed enrollment is 6, but the record does not state how many participants contributed to each outcome, how many specimens were collected or usable, or whether any measurements were excluded. The reason for termination is also not reported. It is therefore not possible to determine whether outcome data were incomplete or how any incomplete measurements were handled.

Analysis populations are not defined in the registry record. It does not say whether analyses were intended to include all enrolled participants, only participants with usable samples, or another group. For laboratory outcomes, clarity about the unit of analysis is important in general: participants, specimens, and individual cell measurements do not represent the same observational unit. The record does not identify which unit was used in any analysis.

Interim analyses and stopping rules are not reported in the registry record. The status is terminated, but that status alone does not explain the decision or imply that a statistical stopping boundary was used. The record also does not report a complete statistical analysis plan. These gaps limit assessment of how outcomes were selected, how incomplete data may have affected estimates, and whether the reported outcome measures correspond to prespecified analyses.

11. What the Result Does, and Does Not, Mean

The registry record establishes that this study focused on laboratory investigation of T cells in blood and bone marrow samples from patients with multiple myeloma. It names strategies to isolate and expand myeloma-specific T cells using autologous B cells as antigen-presenting cells. It also identifies flow cytometry as the method in the primary outcome title and lists an additional measure of cell counts before and after CD3/CD28 stimulation.

These details do not establish a numerical finding. The registry record does not report a percentage, a cell count, an uncertainty interval, or a statistical test result. It therefore does not show how many myeloma-specific T cells were observed, how variable measurements were, or whether measurements differed before and after stimulation. An outcome title describes what was intended to be measured, not the result of that measurement.

The record also does not show that a clinical treatment was tested against a control condition. The listed activities are laboratory techniques, and no like-for-like comparison is identified. The study should not be interpreted as evidence for or against a clinical intervention or as a comparison of patient outcomes. Its stated purpose is to study cells and laboratory approaches; clinical benefit, harm, and effectiveness are not reported in the registry record.

General statistical interpretation requires attention to the estimate, its uncertainty, the population included in the analysis, and the assumptions of the method. None of those result-level details are available for the named outcomes. The listed enrollment of 6 is not by itself enough to determine the precision or representativeness of any laboratory estimate. The record does not report the number of evaluable samples or how participants’ results were summarized.

The terminated status is a registry descriptor, not an explanation of why the study ended and not a result. The reason for termination is not reported in the registry record. Accordingly, the most defensible interpretation is limited: the registry describes a small specimen-based laboratory study and its intended measures, but it does not provide posted numerical results with which to judge those measures.

12. Why This Trial Matters Statistically

This study is statistically notable because it illustrates the difference between an outcome definition and an outcome result. The registry names a percentage of myeloma-specific T cells expanded ex vivo using flow cytometry as its primary measure. That gives readers a broad sense of the intended laboratory question. Without a reported value, denominator, or uncertainty measure, however, the measure cannot be quantitatively interpreted.

The record also highlights why defining the analysis unit matters. A laboratory investigation may involve participants, specimens, and cell-level measurements, but these are not automatically independent observations. General statistical methods need to match the structure of the data. The registry record does not say which unit was analyzed or whether the secondary before-and-after cell counts were paired. That absence prevents evaluation of the model assumptions and of the precision of any result.

The listed enrollment is 6, and the study status is terminated. Neither fact supplies the missing outcome analysis. Enrollment is not a substitute for the number of usable measurements, and termination does not explain whether results were available or why the study ended. These distinctions are important when reading registry records: design and status information can be present even when numerical outcome reporting is not.

Finally, the planning assumptions associated with sample-size illustrations should not be mistaken for the design of this study. The illustrations describe a generic two-arm calculation, while the registry does not identify a like-for-like control comparison. Planning calculations can clarify how assumptions affect future study size, but they cannot establish observed power or provide evidence of a result. In this case, careful separation of laboratory purpose, design information, and unavailable outcome estimates is central to a statistically responsible reading.

13. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpretation is the absence of numerical outcome results. Although the registry lists a primary endpoint and a secondary outcome, it reports no values, uncertainty estimates, or analysis entries. The primary endpoint’s unit, dispersion, detailed description, and population are not specified. As a result, neither the size nor precision of any observed laboratory finding can be assessed.

The registry record also provides limited detail about the study population and specimen flow. It lists enrollment of 6 and identifies patients with multiple myeloma, but eligibility criteria, participant characteristics, the number of specimens collected, and the number evaluable for each outcome are not reported. No conclusions about representativeness or missing observations can be supported from the listed enrollment alone.

The laboratory methods are not described in sufficient detail to evaluate reproducibility. The record names flow cytometry, an immunoenzyme technique, and laboratory biomarker analysis, and the official title refers to autologous B cells as antigen-presenting cells. It does not report detailed assay procedures, cell-classification criteria, quality-control methods, or how the primary percentage was calculated. These details are important for understanding what the measure represents and how it might vary.

The study is classified as “other,” is marked terminated, and does not identify a like-for-like control comparison. The reason for termination, allocation details, analysis populations, missing-data handling, multiplicity procedures, interim analyses, and statistical analysis plan are not reported in the registry record. These limitations constrain interpretation of design and analysis but do not establish that any specific procedure was omitted in the conduct of the research.

14. Related Tutorials

15. Related Statistical Calculators

16. Sources

• ClinicalTrials.gov: Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma — NCT00897910.
• Registry record last updated 2016-01-11; status last verified 2015-12.
• Results first posted 2013-12-12.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

17. Record Summary

The registry record describes a laboratory study of T cells in blood and bone marrow samples from patients with multiple myeloma. Its official title concerns isolating and expanding myeloma-specific T cells using autologous B cells as antigen-presenting cells. Listed techniques include flow cytometry, an immunoenzyme technique, and laboratory biomarker analysis.

The primary outcome is the percentage of myeloma-specific T cells expanded ex vivo using flow cytometry. The secondary outcome concerns cell counts before and after CD3/CD28 stimulation. The primary outcome timeframe describes PBMC collection over 9-12 months and a laboratory component over another year.

The listed enrollment is 6. The registry lists a start date of 2008-04, a primary completion date of 2009-11, and a status of terminated. No numerical outcome results or analysis entries are reported. The reason for termination and the statistical analysis plan are not reported in the registry record.